https://scholars.lib.ntu.edu.tw/handle/123456789/641606
Title: | Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence | Authors: | Qin, Xian-Yang Shirakami, Yohei Honda, Masao Shiou-Hwei Yeh Numata, Kazushi Lai, Ya-Yun Li, Chiao-Ling Wei, Feifei Xu, Yali Imai, Kenji Takai, Koji Chuma, Makoto Komatsu, Nagisa Furutani, Yutaka Gailhouste, Luc Aikata, Hiroshi Chayama, Kazuaki Enomoto, Masaru Tateishi, Ryosuke Kawaguchi, Kazunori Yamashita, Tatsuya Kaneko, Shuichi Nagaoka, Katsuya Tanaka, Motohiko Sasaki, Yutaka Tanaka, Yasuhito Baba, Hideo Miura, Kouichi Ochi, Sae Masaki, Takahiro Kojima, Soichi Matsuura, Tomokazu Shimizu, Masahito PEI-JER CHEN Moriwaki, Hisataka Suzuki, Harukazu |
Keywords: | MYCN; acyclic retinoid; biomarker; hepatocellular carcinoma; liquid biopsy | Issue Date: | 21-Feb-2024 | Source: | International journal of cancer | Abstract: | The proto-oncogene MYCN expression marked a cancer stem-like cell population in hepatocellular carcinoma (HCC) and served as a therapeutic target of acyclic retinoid (ACR), an orally administered vitamin A derivative that has demonstrated promising efficacy and safety in reducing HCC recurrence. This study investigated the role of MYCN as a predictive biomarker for therapeutic response to ACR and prognosis of HCC. MYCN gene expression in HCC was analyzed in the Cancer Genome Atlas and a Taiwanese cohort (N = 118). Serum MYCN protein levels were assessed in healthy controls (N = 15), patients with HCC (N = 116), pre- and post-surgical patients with HCC (N = 20), and a subset of patients from a phase 3 clinical trial of ACR (N = 68, NCT01640808). The results showed increased MYCN gene expression in HCC tumors, which positively correlated with HCC recurrence in non-cirrhotic or single-tumor patients. Serum MYCN protein levels were higher in patients with HCC, decreased after surgical resection of HCC, and were associated with liver functional reserve and fibrosis markers, as well as long-term HCC prognosis (>4 years). Subgroup analysis of a phase 3 clinical trial of ACR identified serum MYCN as the risk factor most strongly associated with HCC recurrence. Patients with HCC with higher serum MYCN levels after a 4-week treatment of ACR exhibited a significantly higher risk of recurrence (hazard ratio 3.27; p = .022). In conclusion, serum MYCN holds promise for biomarker-based precision medicine for the prevention of HCC, long-term prognosis of early-stage HCC, and identification of high-response subgroups for ACR-based treatment. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641606 | ISSN: | 00207136 | DOI: | 10.1002/ijc.34893 |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.